These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31367296)

  • 1. HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.
    Lyu X; Hu M; Peng J; Zhang X; Sanders YY
    Ther Adv Chronic Dis; 2019; 10():2040622319862697. PubMed ID: 31367296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.
    Sanaei M; Kavoosi F
    Iran J Pharm Res; 2021; 20(3):324-336. PubMed ID: 34903992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies.
    Pal D; Raj K; Nandi SS; Sinha S; Mishra A; Mondal A; Lagoa R; Burcher JT; Bishayee A
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).
    Cavasin MA; Stenmark KR; McKinsey TA
    Pulm Circ; 2015 Mar; 5(1):63-72. PubMed ID: 25992271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
    Korfei M; Mahavadi P; Guenther A
    Cells; 2022 May; 11(10):. PubMed ID: 35626663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives.
    Zhang H; Dai X; Qi Y; He Y; Du W; Pang JJ
    J Ophthalmol; 2015; 2015():250812. PubMed ID: 26137316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
    Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors as cancer therapeutics.
    Clawson GA
    Ann Transl Med; 2016 Aug; 4(15):287. PubMed ID: 27568481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylases and mechanisms of regulation of gene expression.
    Chen HP; Zhao YT; Zhao TC
    Crit Rev Oncog; 2015; 20(1-2):35-47. PubMed ID: 25746103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal chemistry advances in targeting class I histone deacetylases.
    Abdallah DI; de Araujo ED; Patel NH; Hasan LS; Moriggl R; Krämer OH; Gunning PT
    Explor Target Antitumor Ther; 2023; 4(4):757-779. PubMed ID: 37711592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC modulation and cell death in the clinic.
    Dell'Aversana C; Lepore I; Altucci L
    Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insights into the Role of Histone Deacetylases as Coactivators of Inflammatory Gene Expression.
    Schmitz ML; de la Vega L
    Antioxid Redox Signal; 2015 Jul; 23(1):85-98. PubMed ID: 24359078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
    Sanaei M; Kavoosi F
    Adv Biomed Res; 2019; 8():63. PubMed ID: 31737580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.